BioLife Solutions, Inc. (NASDAQ:BLFS) CTO Sells $23,660.30 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CTO Sean Werner sold 1,115 shares of BioLife Solutions stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $21.22, for a total transaction of $23,660.30. Following the sale, the chief technology officer directly owned 26,495 shares in the company, valued at approximately $562,223.90. The trade was a 4.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Sean Werner also recently made the following trade(s):

• On Tuesday, June 10th, Sean Werner sold 65 shares of BioLife Solutions stock. The shares were sold at an average price of $23.70, for a total transaction of $1,540.50.
• On Wednesday, May 28th, Sean Werner sold 109 shares of BioLife Solutions stock. The shares were sold at an average price of $22.46, for a total transaction of $2,448.14.

BioLife Solutions Stock Down 0.8%

Shares of NASDAQ:BLFS traded down $0.19 during trading on Thursday, hitting $22.26. The company's stock had a trading volume of 407,093 shares, compared to its average volume of 472,280. The business has a 50 day moving average price of $22.09 and a two-hundred day moving average price of $24.05. The company has a market capitalization of $1.06 billion, a PE ratio of -76.76 and a beta of 1.79. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.74 and a current ratio of 4.73. BioLife Solutions, Inc. has a fifty-two week low of $19.10 and a fifty-two week high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. The firm had revenue of $23.94 million during the quarter, compared to the consensus estimate of $22.22 million. BioLife Solutions had a negative net margin of 11.81% and a negative return on equity of 0.66%. As a group, research analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On BioLife Solutions

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of BioLife Solutions during the fourth quarter worth $31,000. State of Wyoming lifted its position in BioLife Solutions by 353.1% in the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 1,490 shares during the last quarter. US Bancorp DE lifted its position in BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after acquiring an additional 1,528 shares during the last quarter. GAMMA Investing LLC lifted its position in BioLife Solutions by 18.6% in the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock valued at $96,000 after acquiring an additional 663 shares during the last quarter. Finally, Strs Ohio purchased a new stake in BioLife Solutions in the first quarter valued at $153,000. Institutional investors and hedge funds own 93.24% of the company's stock.

Wall Street Analysts Forecast Growth

BLFS has been the subject of several research reports. Wall Street Zen downgraded shares of BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Stephens initiated coverage on shares of BioLife Solutions in a report on Tuesday. They issued an "overweight" rating and a $30.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of BioLife Solutions in a report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $31.00.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.